Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2019
Gene therapy was hailed as a revolution. Then came the bill.
7 April 2019 - Cost of new treatments may run into the millions of dollars. ...
Posted by Michael Wonder on 03 Apr 2019
ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy
3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...
Posted by Michael Wonder on 03 Apr 2019
Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer
2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...
Posted by Michael Wonder on 02 Apr 2019
When is the price of a drug unjust? The average lifetime earnings standard
1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...
Posted by Michael Wonder on 26 Mar 2019
Institute for Clinical and Economic Review to assess upadacitinib and other treatments for rheumatoid arthritis
26 March 2019 - Open Input now being accepted; review will be subject to public deliberation at upcoming CTAF meeting. ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 19 Mar 2019
Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...
Posted by Michael Wonder on 16 Mar 2019
Institute for Clinical and Economic Review publishes revised protocol for assessing unsupported price increases for prescription drugs
15 March 2019 - Through April 19, ICER is accepting public input on which additional price increases should be included ...
Posted by Michael Wonder on 14 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis
14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 13 Mar 2019
Drug price watchdog ICER dives into Trump fueled pharma rebate debate
13 March 2019 - With public and political winds blowing in the same direction, significant reform of the complicated U.S. ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 22 Feb 2019
ICER’s assessment finds Spinraza and Zolgensma provide substantial health benefits for people with spinal muscular atrophy
22 February 2019 - Current pricing of Spinraza would require a substantial discount to meet traditional cost-effectiveness ranges; Zolgensma’s value-based price ...
Posted by Michael Wonder on 22 Feb 2019
ICER to publish upcoming assessment on additive cardiovascular disease therapies
22 February 2019 - Report will be subject of Midwest CEPAC meeting in September; open input now being accepted until ...